Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method

Rezvani,Nayebali; Alibakhshi,Reza; Vaisi‑Raygani,Assad; Bashiri,Homayoon; Saidijam,Massoud

doi:10.3892/ol.2017.5815

Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method

Authors:
- Nayebali Rezvani
- Reza Alibakhshi
- Assad Vaisi‑Raygani
- Homayoon Bashiri
- Massoud Saidijam
View Affiliations

Affiliations: Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan 6517838736, Iran, Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah 6714869914, Iran, Department of Gastroenterology, Kermanshah University of Medical Sciences, Kermanshah 6714869914, Iran
Published online on: March 7, 2017 https://doi.org/10.3892/ol.2017.5815
Pages: 3277-3284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant promoter methylation of genes is a common epigenetic alteration in colorectal cancer (CRC). In the present study, spastic paraplegia 20 (SPG20) promoter-methylated DNA, as a potential diagnostic biomarker, was investigated in plasma and tumor tissue samples from patients with CRC. To the best of our knowledge, the quantification of SPG20 promoter-methylated DNA in plasma samples remains unreported. SPG20 promoter methylation was investigated in 32 paired tumor and healthy adjacent tissues, 37 plasma samples from patients with CRC, and in 37 plasma samples from a healthy control group, using the MethyLight method. The percentage of methylated reference (PMR) values was determined for each sample, and the sensitivity and specificity of this unique biomarker were evaluated. PMR values were significantly higher in plasma samples from patients with CRC compared with in those from the control group (P<0.05). Plasma specimens from patients and healthy controls exhibited median PMR values of 7.7 (95% CI, 4.15‑15.28) and 0.59 (95% CI, 0.14‑1.12), respectively. Notably, the median PMR values were identified as 42.39 (95% CI, 27.69‑72.26) and 3.61 (95% CI, 1.07‑5.29) in tumor and adjacent healthy tissues, respectively. Using receiver‑operating characteristics curve analysis, the area under curve (AUC) was demonstrated to be 0.984 for plasma samples, exhibiting a sensitivity of 81.1% and a specificity of 96.9%. Furthermore, the AUC was 0.996 for tissue samples, revealing a sensitivity of 93.8% and specificity of 99.96%. Results from the present study indicate that the identification of SPG20 promoter-methylated DNA in plasma is a potential diagnostic biomarker for the detection of CRC. Furthermore, the results demonstrate a satisfactory sensitivity and specificity, indicating the importance of SPG20 methylation as a novel noninvasive biomarker.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Pawa N, Arulampalam T and Norton JD: Screening for colorectal cancer: Established and emerging modalities. Nat Rev Gastroenterol Hepatol. 8:711–722. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Stigliano V, Sanchez-Mete L, Martayan A and Anti M: Early-onset colorectal cancer: A sporadic or inherited disease? World J Gastroenterol. 20:12420–12430. 2014. View Article : Google Scholar : PubMed/NCBI
5	Mohebbi M, Nourijelyani K, Mahmoudi M, Moghadaszadeh B, Mohammad K, Zeraati H and Fotouhi A: Time of occurrence and age distribution of digestive tract cancers in northern Iran. Iranian J Publ Health. 37:8–19. 2008.
6	Smith RA, Cokkinides V and Eyre HJ: American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 56:11–25; quiz 49–50. 2006. View Article : Google Scholar : PubMed/NCBI
7	Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
8	Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al: The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 41:178–186. 2009. View Article : Google Scholar : PubMed/NCBI
9	Rakyan VK, Down TA, Balding DJ and Beck S: Epigenome-wide association studies for common human diseases. Nat Rev Genet. 12:529–541. 2011. View Article : Google Scholar : PubMed/NCBI
10	Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR and Rashid A: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 160:1823–1830. 2002. View Article : Google Scholar : PubMed/NCBI
11	Fleischhacker M and Schmidt B: Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta. 1775:181–232. 2007.PubMed/NCBI
12	Shirahata A and Hibi K: Serum vimentin methylation as a potential marker for colorectal cancer. Anticancer Res. 34:4121–4125. 2014.PubMed/NCBI
13	deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, et al: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 55:1337–1346. 2009. View Article : Google Scholar : PubMed/NCBI
14	Herbst A, Rahmig K, Stieber P, Philipp A, Jung A, Ofner A, Crispin A, Neumann J, Lamerz R and Kolligs FT: Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol. 106:1110–1118. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, Park J and Kim DH: Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 15:6185–6191. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO and Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 28:259–272. 2006.PubMed/NCBI
17	Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, Hektoen M, Rognum TO, Meling GI, Hoff G, et al: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 10:852011. View Article : Google Scholar : PubMed/NCBI
18	Lind GE, Raiborg C, Danielsen SA, Rognum TO, Thiis-Evensen E, Hoff G, Nesbakken A, Stenmark H and Lothe RA: SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. 30:3967–3978. 2011. View Article : Google Scholar : PubMed/NCBI
19	Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB and Lind GE: Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics. 9:428–436. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bakowska JC, Jupille H, Fatheddin P, Puertollano R and Blackstone C: Troyer syndrome protein spartin is mono-ubiquitinated and functions in EGF receptor trafficking. Mol Biol Cell. 18:1683–1692. 2007. View Article : Google Scholar : PubMed/NCBI
21	Eastman SW, Yassaee M and Bieniasz PD: A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J Cell Biol. 184:881–894. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tsang HT, Edwards TL, Wang X, Connell JW, Davies RJ, Durrington HJ, O'Kane CJ, Luzio JP and Reid E: The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling. Hum Mol Genet. 18:3805–3821. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hooper C, Puttamadappa SS, Loring Z, Shekhtman A and Bakowska JC: Spartin activates atrophin-1-interacting protein 4 (AIP4) E3 ubiquitin ligase and promotes ubiquitination of adipophilin on lipid droplets. BMC Biol. 8:722010. View Article : Google Scholar : PubMed/NCBI
24	Ciccarelli FD, Proukakis C, Patel H, Cross H, Azam S, Patton MA, Bork P and Crosby AH: The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia. Genomics. 81:437–441. 2003. View Article : Google Scholar : PubMed/NCBI
25	Connell JW, Lindon C, Luzio JP and Reid E: Spastin couples microtubule severing to membrane traffic in completion of cytokinesis and secretion. Traffic. 10:42–56. 2009. View Article : Google Scholar : PubMed/NCBI
26	Sagona AP and Stenmark H: Cytokinesis and cancer. FEBS Lett. 584:2652–2661. 2010. View Article : Google Scholar : PubMed/NCBI
27	Heresbach D, Manfredi S, D'Halluin PN, Bretagne JF and Branger B: Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 18:427–433. 2006. View Article : Google Scholar : PubMed/NCBI
28	Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011. View Article : Google Scholar : PubMed/NCBI
29	Bonetti Reggiani L, Barresi V, Bettelli S, Domati F and Palmiere C: Poorly differentiated clusters (PDC) in colorectal cancer: What is and ought to be known. Diagn Pathol. 11:312016. View Article : Google Scholar : PubMed/NCBI
30	Susan JC, Harrison J, Paul CL and Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22:2990–2997. 1994. View Article : Google Scholar : PubMed/NCBI
31	Grunau C, Clark SJ and Rosenthal A: Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Nucleic Acids Res. 29:E65–E75. 2001. View Article : Google Scholar : PubMed/NCBI
32	Clark SJ: Studying mammalian DNA methylation: Bisulfite modification. CRC Press; Boca Raton: 2004, View Article : Google Scholar
33	Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M and Fuchs CS: Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 8:209–217. 2006. View Article : Google Scholar : PubMed/NCBI
34	Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW: MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28:E322000. View Article : Google Scholar : PubMed/NCBI
35	Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M and Laird PW: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 33:6823–6836. 2005. View Article : Google Scholar : PubMed/NCBI
36	Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, Müller-Holzner E, Widschwendter M and Ehrlich M: DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther. 3:1225–1231. 2004. View Article : Google Scholar : PubMed/NCBI
37	Pfaffl MW: Quantification strategies in real-time polymerase chain reactionApplied Microbiology. Filion M: Caister Academic Press; Norfolk, UK: pp. 53–61. 2012
38	Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI
39	Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS and Heichman KA: Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9:1332011. View Article : Google Scholar : PubMed/NCBI
40	Grutzmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, et al: Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 3:e37592008. View Article : Google Scholar : PubMed/NCBI
41	Kalmar A, Toth K, Wasserkort R, Sipos F, Wichmann B, Valcz G, Tulassay Z and Molnar B: The detection of methylated Septin 9 in tissue and plasma of colorectal neoplasia and its relationship to the amount of free circulating DNA. Cancer Res. 74:1850. 2014. View Article : Google Scholar
42	Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK and Sung JJ: Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 100:2274–2279. 2005. View Article : Google Scholar : PubMed/NCBI
43	Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M and Ito Y: Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 18:1225–1230. 2007.PubMed/NCBI
44	Zhang H, Song YC and Dang CX: Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 10:230–234. 2013. View Article : Google Scholar : PubMed/NCBI
45	Yamashita K and Watanabe M: Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 100:195–199. 2009. View Article : Google Scholar : PubMed/NCBI
46	Yamashita K, Waraya M, Kim MS, Sidransky D, Katada N, Sato T, Nakamura T and Watanabe M: Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study. PLoS One. 9:e1135462014. View Article : Google Scholar : PubMed/NCBI
47	Zhang SY, Lin M and Zhang HB: Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma. Int J Clin Exp Pathol. 8:9404–9409. 2015.PubMed/NCBI
48	Koga Y, Yamazaki N and Matsumura Y: Fecal biomarker for colorectal cancer diagnosis. Rinsho Byori. 63:361–368. 2015.(In Japanese). PubMed/NCBI